A description of the study rationale, design, and methods is given elsewhere [34]
It also puts the brakes on new fat production at the same time
However, certain medications have shorter shelf lives, which limits how long you can stretch out a supply and thus limits the money-saving potentialmore on this later
Summary: Retatrutide is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) that, based on Phase 2 trial data, produces significant appetite suppression and progressive weight loss, alongside gastrointestinal side effects that are most prominent during dose escalation
An observational study of obese T2D patients with concurrent MASLD (metabolic dysfunction-associated steatotic liver disease) showed that 12 weeks of liraglutide significantly increased gut bacterial diversity and shifted the community toward a profile more like healthy individuals ( Bacteroidota and Proteobacteria (class Bacilli also increased), whereas an active comparator (metformin) enriched different taxa ( Fusobacteria and Actinobacteria ) and had a larger effect on network connectivity of the microbiota